This adverse effect of cardiac HIF-1α accumulation raises concerns over the potential pleiotropic effects of the 'HIF stabilizing' inhibitors of Prolyl Hydroxylase currently entering clinical practice for the treatment of anemia in Chronic Kidney Disease, particularly given the increased cardiovascular mortality observed in this patient group. This evidence concerns the gene HIF1A and anemia (phenotype).